NantKwest, Inc. (NASDAQ:NK) Given a $3.00 Price Target at Citigroup Inc.
NantKwest, Inc. (NASDAQ:NK) has been given a $3.00 price objective by investment analysts at Citigroup Inc. in a research note issued to investors on Monday. The brokerage presently has a “sell” rating on the biotechnology company’s stock. Citigroup Inc.’s price objective would suggest a potential downside of 48.98% from the stock’s current price.
A number of other research analysts have also issued reports on the stock. Jefferies Group LLC set a $4.00 target price on shares of NantKwest and gave the company a “hold” rating in a report on Monday, May 8th. Zacks Investment Research upgraded shares of NantKwest from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a report on Tuesday, May 16th. ValuEngine upgraded shares of NantKwest from a “strong sell” rating to a “sell” rating in a report on Wednesday, June 14th. Finally, BidaskClub lowered shares of NantKwest from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $10.79.
Shares of NantKwest (NASDAQ NK) opened at 5.88 on Monday. The firm’s market capitalization is $467.11 million. NantKwest has a 52-week low of $2.71 and a 52-week high of $9.60. The company’s 50-day moving average is $6.79 and its 200 day moving average is $4.88.
In other news, Director Steve Gorlin sold 40,000 shares of the company’s stock in a transaction dated Tuesday, June 20th. The shares were sold at an average price of $7.78, for a total transaction of $311,200.00. Following the completion of the transaction, the director now owns 409,725 shares of the company’s stock, valued at approximately $3,187,660.50. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 70.19% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of NK. Renaissance Technologies LLC increased its stake in NantKwest by 1,884.1% in the first quarter. Renaissance Technologies LLC now owns 486,100 shares of the biotechnology company’s stock worth $1,726,000 after buying an additional 461,600 shares during the period. Vanguard Group Inc. increased its stake in NantKwest by 8.4% in the first quarter. Vanguard Group Inc. now owns 2,082,706 shares of the biotechnology company’s stock worth $7,394,000 after buying an additional 160,510 shares during the period. Northern Trust Corp increased its stake in NantKwest by 67.8% in the second quarter. Northern Trust Corp now owns 304,062 shares of the biotechnology company’s stock worth $2,308,000 after buying an additional 122,906 shares during the period. State Street Corp increased its stake in NantKwest by 52.9% in the second quarter. State Street Corp now owns 341,007 shares of the biotechnology company’s stock worth $2,589,000 after buying an additional 117,946 shares during the period. Finally, Alps Advisors Inc. acquired a new stake in NantKwest during the second quarter worth about $563,000. 20.73% of the stock is owned by institutional investors.
NantKwest Company Profile
Receive News & Ratings for NantKwest Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.